UTHR

Q: What is the price of United Therapeutics (UTHR) today?

The price of United Therapeutics (UTHR) today is R$ 1.675,97, with a variation of -10.8% compared to the last year. The price of United Therapeutics (UTHR) started the year trading around R$ 1.912,39 and today it is at R$ 1.675,97. Follow the real-time price chart, the historical price of United Therapeutics (UTHR), and stock data from Ibovespa and international markets.

Q: When does United Therapeutics (UTHR) pay dividends?

United Therapeutics (UTHR) did not distribute dividends in the last year.

Q: United Therapeutics (UTHR) is it worth it?

Currently, United Therapeutics (UTHR) is priced at R$ 1.675,97, with a P/E of 11,31%, representing a deviation of 15,09% from its historical average P/E. In the last year, the stock showed a variation of -10.8% in its price and distributed R$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -10,80%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How to buy shares of United Therapeutics (UTHR)?

Investing in shares of United Therapeutics (UTHR) can be done in two ways: by buying the stock abroad or the BDR in Brazil (if available). The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.The BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much do 100 shares of United Therapeutics (UTHR) yield today?

The yield of United Therapeutics (UTHR) was 1,55% in the last month, -10,80% in the last year and 191,61% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of R$ 0,00 in dividends, um Dividend Yield de 0,00%.If you wanted to buy 100 shares of United Therapeutics (UTHR) today, the total investment would be based on the current price of R$ 1.675,97.If past performance were to repeat, the return on your investment would be:In 1 year: R$ 149.496,74In 5 years: R$ 488.730,31In 10 years: 344.077,13It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

United Therapeutics Corporation

Price

US$ 309,22

variation (12m)

-10,80%

p/l

11,31

p/vp

1,96

DIVIDEND YIELD

0,00%

quote UTHR

BVMF

UTHR

If you had invested

year ago

6 months

1 year

5 years

10 years

today you would have

today you would have:

*The figure considers the reinvestment of dividends.

profitability of UTHR

1 month

3 months

1 year

2 years

5 years

10 years

profitability

1 month

1,55%

3 months

-2,03%

1 year

-10,80%

2 years

36,82%

5 years

191,61%

10 years

105,30%

real profitability

profitability minus inflation.

1 month

1,55%

3 months

-2,52%

1 year

-15,25%

2 years

24,71%

5 years

113,08%

10 years

21,71%

Indicators UTHR

check out the fundamentals of United Therapeutics shares

P/L

11,31

Sector: -3,27 Industry: -3,27

P/SALES (PSR)

4,57

Sector: -3,77 Industry: -3,77

P/VP

1,96

Sector: 1,74 Industry: 1,74

DIVIDEND YIELD (DY)

0,00%

Sector: - Industry: -

ROA

15,71%

Sector: -63,50% Industry: -63,50%

ROE

17,31%

Sector: -67,23% Industry: -67,23%

ROIC

27,27%

Sector: -2.087,74% Industry: -2.087,74%

Net Margin

40,36%

Sector: -43,34% Industry: -43,34%

GROSS MARGIN

88,98%

Sector: 40,50% Industry: 40,50%

OPERATING MARGIN

50,06%

Sector: -43,21% Industry: -43,21%

P/EBITDA

8,13

Sector: -3,13 Industry: -3,13

P/EBIT

8,52

Sector: -3,41 Industry: -3,41

P/ASSETS

1,78

Sector: 1,29 Industry: 1,29

VPA

159,41

Sector: 1,80 Industry: 1,80

LPA

27,60

Sector: -2,09 Industry: -2,09

EQUITY / ASSETS

0,91

Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

15,72%

Sector: - Industry: -

CAGR PROFITS 5 YEARS

19,26%

Sector: - Industry: -

FAIR PRICE OF United Therapeutics ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 309,22

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

1,75%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

UTHR indicators history

DRAG THE FRAME TO SEE MORE DATA

comparator of Stocks

DRAG THE FRAME TO SEE MORE DATA

	p/l	p/vp	ROE	dy	market value	Net Margin
JNJ	19,04	5,50	28,88%	2,80%	US$ 431,37 B	25,00%
PFE	13,45	1,62	12,08%	6,68%	US$ 144,63 B	16,84%
ABBV	79,66	228,58	286,94%	3,38%	US$ 334,19 B	7,31%
NVO	15,51	9,75	62,86%	2,83%	US$ 253,39 B	35,63%
MRK	13,05	4,36	33,44%	3,75%	US$ 214,13 B	25,79%
BMY	19,31	5,58	28,87%	5,13%	US$ 97,52 B	10,58%
GILD	22,64	7,29	32,21%	2,72%	US$ 142,89 B	21,87%
AZN	30,26	5,60	18,51%	1,91%	US$ 251,01 B	14,68%
ZTS	26,68	14,00	52,48%	1,19%	US$ 69,70 B	27,83%
HALO	15,59	26,12	167,47%	0,00%	US$ 8,69 B	47,28%
REGN	13,88	2,07	14,89%	0,30%	US$ 61,90 B	31,37%
AMGN	23,87	21,27	89,11%	3,15%	US$ 158,02 B	18,96%
VRTX	27,92	5,91	21,18%	0,00%	US$ 101,55 B	31,86%
ADMA	20,53	10,77	52,45%	0,00%	US$ 4,29 B	44,06%
MCK	27,24	-99,86	-366,63%	0,41%	US$ 86,18 B	0,84%
BIIB	13,38	1,16	8,68%	0,00%	US$ 20,48 B	15,31%
CAH	22,58	-13,38	-59,26%	1,37%	US$ 35,25 B	0,70%

comparison of UTHR with indexes

If you had invested (change) 2 years a year ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.

dividend history UTHR dividend history

Current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY United Therapeutics

United Therapeutics Corporation

Average user rating I10

4.0 (1 people)

Estados Unidos

29 years

Foundation: 1996

1999

Year of debut on the stock exchange - 26 years

920

Employees

The Company United Therapeutics Corporation (Estados Unidos), is listed on Nasdaq with a market value of $ 14,05 Billions, having a net worth of $ 7,17 Billions.

With a total of 920 employees, the company is listed in the sector of Cuidados de saúde and categorized in industry of Biotecnologia.

In the last 12 months the Company had a revenue of $ 3,08 Billions, which generated a profit in the amount of $ 1,24 Billion.

As for its main indicators, the Company has a P/E ratio of 11,31, a P/B ratio of 1,96 and in the last 12 months the Company did not pay dividends.

The Company is traded through the ticker UTHR.

Market value

US$ 14,05 Billions

Net worth

US$ 7,17 Billions

US$ 7.173.600.000,00

Assets

US$ 7,91 Billions

US$ 7.908.000.000,00

Total Number of Shares

45,00 Milhões

45.000.000

Average Daily Trading Volume

US$ 600,94 Thousand

US$ 600.944,84

Sector

Cuidados de saúde

Industry

Biotecnologia

UTHR

UTHR revenue and profits

UTHR results

DRAG THE FRAME TO SEE MORE DATA

UTHR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

US$ - -0,00% (12M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 680,52 24,27% (12M)

P/L

27,24

0,41%

ROE

-366,63%

P/VP

-99,86

CAH - Cardinal Health

US$ 147,49 36,56% (12M)

P/L

22,58

1,37%

ROE

-59,26%

P/VP

-13,38

JNJ - Johnson & Johnson

US$ 176,49 12,66% (12M)

P/L

19,04

2,80%

ROE

28,88%

P/VP

5,50

MRK - Merck & Co.

US$ 84,99 --23,85% (12M)

P/L

13,05

3,75%

ROE

33,44%

P/VP

4,36

PFE - Pfizer

US$ 24,92 --5,92% (12M)

P/L

13,45

6,68%

ROE

12,08%

P/VP

1,62

AZN - AstraZeneca

US$ 80,05 --5,68% (12M)

P/L

30,26

1,91%

ROE

18,51%

P/VP

5,60

ABBV - AbbVie

US$ 208,36 10,15% (12M)

P/L

79,66

3,38%

ROE

286,94%

P/VP

228,58

BFRA - Biofrontera

US$ - -0,00% (12 M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 680,52 24,27% (12 M)

P/L

27,24

0,41%

ROE

-366,63%

P/VP

-99,86

CAH - Cardinal Health

US$ 147,49 36,56% (12 M)

P/L

22,58

1,37%

ROE

-59,26%

P/VP

-13,38

JNJ - Johnson & Johnson

US$ 176,49 12,66% (12 M)

P/L

19,04

2,80%

ROE

28,88%

P/VP

5,50

MRK - Merck & Co.

US$ 84,99 --23,85% (12 M)

P/L

13,05

3,75%

ROE

33,44%

P/VP

4,36

PFE - Pfizer

US$ 24,92 --5,92% (12 M)

P/L

13,45

6,68%

ROE

12,08%

P/VP

1,62

AZN - AstraZeneca

US$ 80,05 --5,68% (12 M)

P/L

30,26

1,91%

ROE

18,51%

P/VP

5,60

ABBV - AbbVie

US$ 208,36 10,15% (12 M)

P/L

79,66

3,38%

ROE

286,94%

P/VP

228,58

Common Questions

What is the price of United Therapeutics (UTHR) today?

The price of United Therapeutics (UTHR) today is R$ 1.675,97, with a variation of -10.8% compared to the last year. The price of United Therapeutics (UTHR) started the year trading around R$ 1.912,39 and today it is at R$ 1.675,97. Follow the real-time price chart, the historical price of United Therapeutics (UTHR), and stock data from Ibovespa and international markets.

When does United Therapeutics (UTHR) pay dividends?

United Therapeutics (UTHR) did not distribute dividends in the last year.

United Therapeutics (UTHR) is it worth it?

Currently, United Therapeutics (UTHR) is priced at R$ 1.675,97, with a P/E of 11,31%, representing a deviation of 15,09% from its historical average P/E. In the last year, the stock showed a variation of -10.8% in its price and distributed R$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -10,80%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy shares of United Therapeutics (UTHR)?

Investing in shares of United Therapeutics (UTHR) can be done in two ways: by buying the stock abroad or the BDR in Brazil (if available). The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

The BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 shares of United Therapeutics (UTHR) yield today?

The yield of United Therapeutics (UTHR) was 1,55% in the last month, -10,80% in the last year and 191,61% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of R$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 shares of United Therapeutics (UTHR) today, the total investment would be based on the current price of R$ 1.675,97.

If past performance were to repeat, the return on your investment would be:

In 1 year: R$ 149.496,74
In 5 years: R$ 488.730,31
In 10 years: 344.077,13

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

UTHR

United Therapeutics Corporation

Price

variation (12m)

p/l

p/vp

DIVIDEND YIELD

profitability of UTHR

check out the fundamentals of United Therapeutics shares

P/L

P/SALES (PSR)

P/VP

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

Net Margin

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSETS

VPA

LPA

EQUITY / ASSETS

CAGR REVENUES 5 YEARS

CAGR PROFITS 5 YEARS

Graham's Fair Price

If you had invested (change) 2 years a year ago, today you would have

Current DY: 0,00%

5-year average DY: 0,00%

ABOUT THE COMPANY United Therapeutics

United Therapeutics Corporation

Estados Unidos

29 years

1999

920

PROFIT X PRICE UTHR

UTHR results

UTHR cash flow

evolution of assets - UTHR

UTHR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

AZN - AstraZeneca

ABBV - AbbVie

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

AZN - AstraZeneca

ABBV - AbbVie

Common Questions

Tudo que o investidor precisa em um só lugar

Pague 2, Leve 3

Anual

Valor total R$ 238,80